DJDoosoo Jeon

Doosoo Jeon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Doosoo Jeon has a total of 169 co-authors. Here are the top co-authors by number of shared publications:

  • Woo Hyun Cho

    Transplant Research Center, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea

    12 shared publications
  • Hye Ju Yeo

    Transplant Research Center, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea

    11 shared publications
  • Yun Seong Kim

    From the Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Pusan National University School of Medicine, Transplantation Research Center, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea

    11 shared publications
  • Jeongha Mok

    Department of Internal Medicine, Pusan National University Hospital, Busan, Korea

    7 shared publications
  • Seong Hoon Yoon

    Division of Pulmonology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan 50612, Republic of Korea

    6 shared publications
  • Seung Eun Lee

    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Pusan National University School of Medicine, Transplantation Research Center, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea

    6 shared publications

Latest Publications

  • Computed Tomography–Derived Psoas Muscle Quantity, Attenuation, and 1 Year Mortality in Venovenous Extracorporeal Membrane Oxygenation

    by Jin Ho Jang, Eunjeong Choi, Woo Hyun Cho, Doosoo Jeon, Yun Seong Kim, Hye Ju Yeo

    Computed tomography (CT)–derived skeletal muscle characteristics may provide prognostic information in patients receiving venovenous extracorporeal membrane oxygenation (VV ECMO), but the relative contributions of muscle quantity and attenuation remain uncertain. We retrospectively studied adults who received VV ECMO for severe respiratory failure between 2014 and 2023 and underwent abdominal CT within 48 h before ECMO initiation. Psoas muscle index (PMI) and attenuation were measured using an artificial intelligence–based pipeline, and combined PMI–attenuation phenotypes were evaluated for 1 year mortality. Among 92 patients, 53 (57.6%) died within 1 year. In Cox proportional hazards models adjusted for age, sex, and initial Sequential Organ Failure Assessment score and stratified by bridge-to-transplantation status, higher PMI (adjusted hazard ratio [aHR] per standard deviation increase, 0.58; 95% confidence interval [CI], 0.41–0.82) and higher attenuation (aHR per 5 Hounsfield unit increase, 0.87; 95% CI, 0.77–0.97) were associated with lower 1 year mortality. When modeled simultaneously, PMI remained significant, whereas attenuation did not. The low PMI/low attenuation phenotype had the highest mortality risk (aHR, 5.30; 95% CI, 2.10–13.34). PMI showed a more robust association with 1 year mortality, while combined PMI–attenuation phenotyping may identify a particularly high-risk subgroup.

  • Open Access

    Rehabilitation during extracorporeal membrane oxygenation: bridging the gap between life support and functional recovery

    by Jin Ho Jang, Eunjeong Choi, Eunjeong Son, Seong Hoon Yoon, Hee Yun Seol, Seung Eun Lee, Woo Hyun Cho, Doosoo Jeon, Yun Seong Kim, Hye Ju Yeo

    Rehabilitation during extracorporeal membrane oxygenation (ECMO) has become a promising intervention to mitigate the profound physical and functional decline that occurs with prolonged critical illness. With the wider adoption of ECMO, interest has grown in integrating early mobilization into routine care practices to preserve muscle mass, reduce intensive care unit-acquired weakness, and improve long-term patient outcomes. Emerging observational data indicate that structured rehabilitation protocols—including passive and active mobilization—are feasible and safe, including for individuals undergoing femoral cannulation. Nevertheless, multiple obstacles, including patient instability, technical constraints, staffing limitations, and gaps in clinical knowledge, impede broader implementation. Although the theoretical rationale and initial data are compelling, further robust randomized controlled trials are essential to establish the definitive efficacy, best-practice protocols, and cost-effectiveness of rehabilitation interventions in ECMO-supported patients.


  • Open Access

    Drug Resistance in Extrapulmonary Tuberculosis in Korea, 2010–2019: A Comparison With Pulmonary Tuberculosis

    by Saerom Kim, Doosoo Jeon, Taehoon Lee, Seung Jun Lee, Ho Young Lee, Bo Hyoung Kang, Jeongha Mok

    Kim S, et al. J Korean Med Sci. 2026 Jan;41:e60. https://doi.org/10.3346/jkms.2026.41.e60


  • Open Access

    The impact of population ageing on tuberculosis incidence, mortality, and case fatality in South Korea: a nationwide retrospective study

    by Seung Won Lee, Doosoo Jeon, Hongjo Choi, Chiwook Chung, Jeongha Mok, Dawoon Jeong, Hojoon Sohn, Young Ae Kang

    Background: This study investigated the effect of population ageing on the epidemiology of tuberculosis (TB) in South Korea. Methods: We conducted a retrospective cohort study using an integrated database from three national databases. We analysed trends in age-specific TB incidence, mortality, case fatality rates and risk factors for all-cause mortality among 328 637 patients with drug-susceptible TB from 2011 to 2020. Results: From 2011 to 2020, the proportion of patients aged ≥65 years increased from 30.5% to 50.7% of TB cases and from 74.3% to 86.8% of deaths. The TB incidence rate decreased from 90.3 to 39.5 per 100 000 (average annual per cent change (AAPC) −8.5%; 95% confidence interval (CI) −9.2 to −7.7). The crude mortality rate remained largely unchanged, shifting from 4.6 to 5.4 per 100 000 (AAPC 1.6%; 95% CI −0.1 to 3.1). The case fatality rate increased from 5.1% to 13.5% (AAPC 11.3%; 95% CI 10.5 to 12.1). Although incidence and mortality declined across all age groups, the rate of decline slowed with increasing age. Patients aged ≥80 years showed the slowest decline in incidence (AAPC −4.3%; 95% CI −5.4 to −3.5) and stagnation in mortality (AAPC 0.5%; 95% CI −1.4 to 2.2). Conclusions: This study highlights the challenges of population ageing on TB control, including increasing case fatality rates and slower declines in TB incidence and mortality. These findings call for a reassessment of current strategies to address the needs of the elderly.


  • Open Access

    Comparison of Patients Who Were Not Evaluated and Lost to Follow-Up with Multidrug/Rifampin-Resistant Tuberculosis in South Korea

    by Hongjo Choi, Jeongha Mok, Young Ae Kang, Dawoon Jeong, Hee-Yeon Kang, Hee Jin Kim, Hee-Sun Kim, Doosoo Jeon

    Choi H, et al. Yonsei Med J. 2025 Jan;66(1):16-24. https://doi.org/10.3349/ymj.2024.0048


  • Open Access

    Navigating the Modern Landscape of Sepsis: Advances in Diagnosis and Treatment

    by Jin Ho Jang, Eunjeong Choi, Taehwa Kim, Hye Ju Yeo, Doosoo Jeon, Yun Seong Kim, Woo Hyun Cho

    Sepsis poses a significant threat to human health due to its high morbidity and mortality rates worldwide. Traditional diagnostic methods for identifying sepsis or its causative organisms are time-consuming and contribute to a high mortality rate. Biomarkers have been developed to overcome these limitations and are currently used for sepsis diagnosis, prognosis prediction, and treatment response assessment. Over the past few decades, more than 250 biomarkers have been identified, a few of which have been used in clinical decision-making. Consistent with the limitations of diagnosing sepsis, there is currently no specific treatment for sepsis. Currently, the general treatment for sepsis is conservative and includes timely antibiotic use and hemodynamic support. When planning sepsis-specific treatment, it is important to select the most suitable patient, considering the heterogeneous nature of sepsis. This comprehensive review summarizes current and evolving biomarkers and therapeutic approaches for sepsis.


  • Open Access

    Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea

    by Eunjeong Son, Hongjo Choi, Jeongha Mok, Young Ae Kang, Dawoon Jeong, Doosoo Jeon

    Background/Aims: This study aimed to investigate the timing and predictors of death during treatment among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB) in South Korea.Methods: This was a retrospective cohort study that included MDR/RR-TB cases notified between 2011 and 2017 in South Korea.Results: Among 7,226 MDR/RR-TB cases, 699 (9.7%) died at a median of 167 days (IQR 51–358 d) from the initiation of MDR-TB treatment. The cumulative proportion of all-cause death was 35.5% at 90 days and 52.8% at 180 days from treatment initiation. TB-related deaths occurred at a median of 133 days (IQR 32–366 d), which was significantly earlier than the median of 184 days (IQR 68–356 d) for non-TB-related deaths (p = 0.002). In a multivariate analysis, older age was the factor most strongly associated with death, with those aged ≥ 75 years being 68 times more likely to die (aHR 68.11, 95% CI 21.75–213.26), compared those aged ≤ 24 years. In addition, male sex, comorbidities (cancer, human immunodeficiency virus, and end stage renal disease), the lowest household income class, and TB-specific factors (previous history of TB treatment, smear positivity, and fluoroquinolone resistance) were identified as independent predictors of all-cause death.Conclusions: This nationwide study highlights increased deaths during the intensive phase and identifies high-risk groups including older people and those with comorbidities or socioeconomic vulnerabilities. An integrated and comprehensive strategy is required to reduce mortality in patients with MDR/RR-TB, particularly focusing on the early stages of treatment and target populations.


  • Open Access

    QMAC-DST for Rapid Detection of Drug Resistance in Pulmonary Tuberculosis Patients: A Multicenter Pre–Post Comparative Study

    by Nakwon Kwak, Sangyeop Lee, Suyeoun Kim, Eunbee Song, Jae-Joon Yim, Tae Sun Shim, Doosoo Jeon, Byung Woo Jhun, Kwang-Hyuk Seok, Saerom Kim, et al.

    Background/Objectives: This study explores the impact of QMAC-DST, a rapid, fully automated phenotypic drug susceptibility test (pDST), on the treatment of tuberculosis (TB) patients. Methods: This pre–post comparative study, respectively, included pulmonary TB patients who began TB treatment between 1 December 2020 and 31 October 2021 (pre-period; pDST using the Löwenstein–Jensen (LJ) DST (M-kit DST)) and between 1 November 2021 and 30 September 2022 (post-period; pDST using the QMAC-DST) in five university-affiliated tertiary care hospitals in South Korea. We compared the turnaround times (TATs) of pDSTs and the time to appropriate treatment for patients whose anti-TB drugs were changed based on these tests between the groups. All patients were permitted to use molecular DSTs (mDSTs). Results: A total of 182 patients (135 in the M-kit DST group and 47 in the QMAC-DST group) were included. The median TAT was 36 days for M-kit DST (interquartile range (IQR), 30–39) and 12 days for QMAC-DST (IQR, 9–15), with the latter being significantly shorter (p < 0.001). Of the total patients, 10 (5.5%) changed their anti-TB drugs based on the mDST or pDST results after initiating TB treatment (8 in the M-kit DST group and 2 in the QMAC-DST group). In the M-kit DST group, three (37.5%) patients changed anti-TB drugs based on the pDST results. In the QMAC-DST group, all changes were due to mDST results; therefore, calculating the time to appropriate treatment for patients whose anti-TB drugs were changed based on pDST results was not feasible. In the QMAC-DST group, 46.8% of patients underwent the first-line line probe assay compared to 100.0% in the M-kit DST group (p < 0.001), indicating that rapid QMAC-DST results provide quicker assurance of the ongoing treatment by confirming susceptibility to the current anti-TB drugs. Conclusions: QMAC-DST delivers pDST results more rapidly than LJ-DST, ensuring faster confirmation for the current treatment regimen.

  • Open Access

    Initial Tumor Necrosis Factor-Alpha and Endothelial Activation Are Associated with Hemorrhagic Complications during Extracorporeal Membrane Oxygenation

    by Jin Ho Jang, Kyung-Hwa Shin, Hye Rin Lee, Eunjeong Son, Seung Eun Lee, Hee Yun Seol, Seong Hoon Yoon, Taehwa Kim, Woo Hyun Cho, Doosoo Jeon, et al.

    Studies on inflammatory markers, endothelial activation, and bleeding during extracorporeal membrane oxygenation (ECMO) are lacking. Blood samples were prospectively collected after ECMO initiation from 150 adult patients who underwent ECMO for respiratory failure between 2018 and 2021. After excluding patients who died early (within 48 h), 132 patients were finally included. Their tumor necrosis factor-alpha (TNF-α), tissue factor (TF), soluble thrombomodulin (sTM), and E-selectin levels were measured. A Cox proportional hazards regression model was used to estimate the hazard ratio for hemorrhagic complications during ECMO. The 132 patients were divided into hemorrhagic (n = 23, H group) and non-complication (n = 109, N group) groups. The sequential organ failure assessment score, hemoglobin level, and ECMO type were included as covariates in all Cox models to exclude the effects of clinical factors. After adjusting for these factors, initial TNF-α, TF, sTM, E-selectin, and activated protein C levels were significantly associated with hemorrhagic complications (all p < 0.001). TNF-α, TF, and E-selectin better predicted hemorrhagic complications than the model that included only the aforementioned clinical factors (clinical factors only (area under the curve [AUC]: 0.804), reference; TNF-α (AUC: 0.914); TF (AUC: 0.915); E-selectin (AUC: 0.869)). Conclusions: TNF-α levels were significantly predictive of hemorrhagic complications during ECMO.